ISSN:
1573-0646
Keywords:
9-AC
;
9-aminocamptothecin
;
camptothecin
;
colorectal cancer
;
phase II
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Abstract 9-Aminocamptothecin (9-AC) is a camptothecin derivative with broad antitumor activity in preclinical studies. Prior investigations suggested that prolonged maintenance of 9-AC lactone plasma concentrations above 10 nmol/l and frequent administration of the drug are important determinants of antitumor activity. Our phase II study, therefore, examined a 5-day continuous infusion of 9-AC weekly for 3 weeks in patients with advanced colorectal cancer. Eighteen patients previously untreated for metastatic disease received 480 μg/m2/day of 9-AC. No responses were observed in 17 evaluable patients. Severe toxicities included granulocytopenia, nausea, vomiting and diarrhea. The median absolute granulocyte count (AGC) nadir was 2,300/μl (range 0–9,000/μl) and occurred on day 10. Eight patients received an escalated dose of 600 μg/m2/day. The median AGC nadir at the escalated dose was 1,500/μl (range: 300–2,700/μl) and occurred on day 22. The median number of courses given was 2 (range: 1–8); and the median time to disease progression was 8 weeks (range: 1–40 weeks). 9-AC administered by this schedule lacked antitumor activity in patients with advanced colorectal carcinomas.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1006248700232
Permalink